Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…Abstract Number: 2835 • 2015 ACR/ARHP Annual Meeting
Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Background/Purpose: Previous reports of RAPID-PsA (NCT01087788) have demonstrated the efficacy of certolizumab pegol (CZP) in patients (pts) with psoriatic arthritis (PsA) over 96 weeks (wks),1…Abstract Number: 2836 • 2015 ACR/ARHP Annual Meeting
Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis
Background/Purpose: ABILITY-2 has demonstrated the efficacy of adalimumab (ADA) vs. placebo (PBO) over 12 weeks (wk) in patients (pt) with peripheral spondyloarthritis (pSpA)1 and sustained…Abstract Number: 2837 • 2015 ACR/ARHP Annual Meeting
Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Background/Purpose: Anti-TNF agents are efficacious in the treatment of ankylosing spondylitis (AS). The switch to another TNF blockage can be an alternative in cases of…Abstract Number: 2838 • 2015 ACR/ARHP Annual Meeting
Evidence of Serological IL-23/IL-17 Axis Activation in Ankylosing Spondylitis Patients with Long-Term TNF Blockade: The Missing Therapy Target?
Background/Purpose: Spondyloarthritis (Spa) is a group of inflammatory diseases in which ankylosing spondylitis (AS) is the prototype. Despite recent advances in pathophysiology and treatment, this…Abstract Number: 2839 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of…Abstract Number: 2840 • 2015 ACR/ARHP Annual Meeting
Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), a phosphodiesterase 4 inhibitor, helps regulate the immune responses in psoriatic arthritis (PsA). PALACE 1-3 compared APR efficacy/safety with placebo in patients…Abstract Number: 2841 • 2015 ACR/ARHP Annual Meeting
Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Background/Purpose: Over the past decade, the treatment of PsA has improved significantly. The purpose of this study was to describe real-world treatment patterns among PsA…Abstract Number: 2842 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
Background/Purpose: Several studies have demonstrated that Tumor Necrosis Factor Inhibitors (TNFi) are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). However, few investigations have directly compared ankylosing…Abstract Number: 2843 • 2015 ACR/ARHP Annual Meeting
Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated clear efficacy and good tolerability in psoriatic arthritis (PsA) and psoriasis. Longer term data are…Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…Abstract Number: 2845 • 2015 ACR/ARHP Annual Meeting
A Randomized, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of Etoricoxib in Patients with Ankylosing Spondylitis
Background/Purpose: Etoricoxib 90 mg, a selective COX-2 inhibitor, provides symptom relief in ankylosing spondylitis (AS) patients. A prior study established etoricoxib 90 mg as safe…Abstract Number: 2846 • 2015 ACR/ARHP Annual Meeting
Modifications to Biologic Therapy and Economic Implications in Psoriatic Arthritis Patients
Background/Purpose: Limited information exists on the long term real-world treatment patterns of biologics for psoriatic arthritis (PsA) in the US population. We assessed medication persistence…Abstract Number: 2847 • 2015 ACR/ARHP Annual Meeting
Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study
Background/Purpose: Ankylosing spondylitis (AS) is associated with a significant burden of illness and has limited treatment options. The identification of predictors of response to anti-tumor necrosis…Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
ACR Meeting Abstracts